680 results on '"Bocci, Guido"'
Search Results
102. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens
103. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle
104. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN–38 on endothelial and cancer cells
105. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer
106. Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma
107. Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation
108. Abstract 2622: Paclitaxel directed screening to identify novel anti-cancer drugs
109. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer
110. Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?
111. Overexpression and Functional Relevance of Somatostatin Receptor-1, -2, and -5 in Endometrium and Endometriotic Lesions
112. Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
113. METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
114. Endometriosis Index: A software-derived score to predict the presence and severity of the disease
115. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis
116. Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue
117. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
118. Discovery and development of the cardiovascular system with a focus on angiogenesis: a historical overview
119. MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA
120. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate
121. Vascular endothelial growth factor pharmacogenetics:: a new perspective for anti-angiogenic therapy
122. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma
123. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
124. Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
125. Importance of Preclinical Investigations of the Integration of Capecitabine into Polychemotherapy Regimens
126. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
127. Drug therapeutic failures in emergency department patients: A university hospital experience
128. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine
129. Biologic Basis of Ovarian Metastasis of Colorectal Cancer
130. Definition of the microvascular pattern of the normal human adult mammary gland
131. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
132. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
133. Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma.
134. Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time
135. Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics
136. Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells
137. May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
138. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
139. Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation
140. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine
141. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
142. Abstract 10: Evaluation of metronomic chemotherapy regimens in preclinical orthotopically implanted colon cancer models, and in patient-derived xenografts
143. Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors
144. DEVEC metronomic schedule for aggressive B and T-cell lymphomas.
145. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
146. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo
147. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
148. Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans
149. Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World
150. Prevention of Capecitabine Toxicity Using a 5-FU Test Dose
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.